Skip to main content

SAB Biotherapeutics, Inc.

corporate_fare Company Profile

SAB Biotherapeutics, Inc.

SABS·NASDAQ·Life Sciences·CIK 0001833214

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company that develops multi-specific, high-potency human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's programs are based on mechanisms of action that have achieved proof-of-concept in clinical trials. SAB Biotherapeutics focuses on developing product candidates for disease targets where a differentiated approach can be either first-in-class against novel targets or best-in-class against complex targets, including type 1 diabetes (T1D) and other autoimmune disorders. Its lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach aimed at delaying onset and potentially preventing disease progression of Stage 3 T1D patients. The company uses advanced genetic engineering and antibody science to develop a proprietary technology capable of producing disease-targeted hIgG in large quantities without human plasma donors. This technology utilizes the human immune response to generate novel therapeutic candidates. SAB Biotherapeutics has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine™, to produce hIgG, with its production platform driving IgG1 production across its pipeline. This differentiated approach using polyclonal antibodies has no biosimilar pathway. The proprietary platform can generate additional novel therapeutic candidates by utilizing the human immune response to generate the optimal repertoire of hIgG for drug targets. The drug development production system generates a diverse repertoire of specifically targeted, high-potency hIgGs that can bind to multiple sites on targeted immunogens.

SAB Biotherapeutics, Inc. (NASDAQ:SABS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for SABS at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • SAB Biotherapeutics Discloses Strong Cash Position and Extended Runway for T1D Program
  • SAB Biotherapeutics Strengthens Board with New Chair David Zaccardelli and Director Rita Jain

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
$13.27M
Diluted EPS
-$0.79
Op. Cash Flow
-$44.78M
Free Cash Flow
-$45.71M
Operating Income
-$48.95M
Cash & Equivalents
$10.5M
Debt / Equity
0.00×
Shares Outstanding
47.61M sh
Source: 10-K · filed 2026-03-09 · accession 0001833214-26-000003
$2.74 -5.84% today
52-week range · as of 2026-11-05 $2.44 – $5.15
Market cap
$253.15M
Volume
874.6K (1.2× avg)
3-mo avg 717.1K
Live data · 2026-11-22 12:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SABS - Filings & News (Page 2)

SABS
Jan 12, 2026, 4:47 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.74
Real-time Price: $2.74 info
Change: -$1.00 (-27%) info
Market Cap: $253.15M info
SABS
Jan 07, 2026, 8:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.79
Real-time Price: $2.74 info
Change: -$1.05 (-28%) info
Market Cap: $253.15M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets